Study Reaffirms Effectiveness of Mpox Vaccine

New research reaffirms the effectiveness of the Mpox vaccine. For people who either received the vaccine or had a previous infection the Mpox virus was less likely to cause severe illness. Two other studies showed that two doses of the vaccine were 66-85% effective at preventing Mpox infections. Mpox typically presents in the early stages as fever, muscle aches and sore throat. Often rashes and blisters develop on the face before spreading throughout the body. In more serious cases, the virus can cause brain inflammation, seizures or death. Over the last 16 months, 87,000 cases of mpox have been confirmed across 112 countries. The vast majority of those infected have been sexually active gay and bisexual men. Mpox spreads through skin-to-skin or bodily fluid contact.